NCT06851221

Brief Summary

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 5, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2024

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

February 21, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 28, 2025

Completed
Last Updated

February 28, 2025

Status Verified

February 1, 2025

Enrollment Period

3.6 years

First QC Date

February 21, 2025

Last Update Submit

February 26, 2025

Conditions

NeuroblastomaEwing Sarcoma

Outcome Measures

Primary Outcomes (1)

  • expression of beta3-adrenoreceptor

    from enrollment to the performance of the analysis that can take up to 6 weeks

Study Arms (1)

biological samples analysis

OTHER
Diagnostic Test: beta3 expression

Interventions

beta3 expressionDIAGNOSTIC_TEST

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

biological samples analysis

Eligibility Criteria

Age0 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • diagnosis of Ewing sarcoma or neuroblastoma

You may not qualify if:

  • sieropositivity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laboratorio traslazionale in oncoematologia

Florence, Italy, 50139, Italy

Location

MeSH Terms

Conditions

NeuroblastomaSarcoma, Ewing

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors, Primitive, PeripheralNeuroectodermal Tumors, PrimitiveNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueOsteosarcomaNeoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueSarcoma

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Traslational oncoematology laboratory

Study Record Dates

First Submitted

February 21, 2025

First Posted

February 28, 2025

Study Start

August 5, 2020

Primary Completion

March 5, 2024

Study Completion

March 5, 2024

Last Updated

February 28, 2025

Record last verified: 2025-02

Locations

IT(1)